MFDA Issues Public Advisory on Indian Medication Alert
The Maldives Food and Drug Authority (MFDA) has released a public advisory following an alert from India’s Central Drugs Standard Control Organisation (CDSCO) about quality concerns with 16 specific medications.
In a statement yesterday, the MFDA confirmed that it had conducted an evaluation to determine whether any of the affected drugs were imported into the Maldives. While none were found to have entered the country through official channels, the authority urged the public to exercise caution, especially given that many Maldivians seek medical treatment in India and may bring back medications for personal use.
advertisement
pic.twitter.com/3pz956Qdqi— MFDA (@MFDA_mv) October 2, 2024
The medications highlighted in the alert include:
- Pulmosil (Sildenafil Injection)
- Pantocid (Pantoprazole Tablets IP)
- Ursocol 300 (Ursodeoxycholic Acid Tablets IP)
- Telma H (Telmisartan 40 mg and Hydrochlorothiazide 12.5 mg Tablets IP)
- Deflazacort Tablets (Defcort 6 Tablets)
- Paziva-40
- Pantomed-40
- Cefixime Oral Suspension IP (Dry Syrup)
- Moxymed CV
- Frusemide Injection IP 20 mg
- Kudajarishtam
- Tab Nodosis
- Haridrakhandam
- Pantoprazole Inj. BP 40 mg
- Yogaraja Guggulu
- PANCEF-OF
The advisory follows a previous notice issued by the MFDA, which listed an additional 48 medications manufactured in India that were found to be substandard, spurious, adulterated, or misbranded.
As part of its response, the MFDA announced efforts to enhance inspection measures at ports through which medicines enter the country.
